Generics will hurt Glivec in China, docs say; Bayer evaluates Adempas in new indication;

@FiercePharma: Top-read special report Monday: The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: ICYMI yesterday: AstraZeneca chief bristles at tying exec pay to Pfizer's spurned £55-per-share bid. Story | Follow @TracyStaton

@EricPFierce: FDA catches Wockhardt U.S. plant up to same tricks as banned Indian plants. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Valeant's Allergan bid gets hostile as Ackman makes a play for board control. Report | Follow @CarlyHFierce

@JustinHFierce: Norway's Vaccibody and Jersey's Phibro ink agreement for developing novel poultry vaccines to corner $1b market. Release | Follow @JustinHFierce

> Surveyed hematologists in China expect generics of Novartis' ($NVS) Glivec to significantly dent the drug's market share in chronic myeloid leukemia. Release

> Bayer is starting trials to investigate the use of Adempas in patients with symptomatic pulmonary hypertension or PH associated with idiopathic interstitial pneumonia. More

> Slovenian generics company Krka will delist 7.4% of its shares and buy back up to 10% more over the next three years. Report

> The EMA has accepted Vanda Pharmaceuticals' ($VNDA) marketing app for sleep disorder drug Hetlioz. More

> India's Aurobindo Pharma has won FDA approval to market a generic of AbbVie's ($ABBV) Depakote ER tablets in the U.S. Report

Medical Device News

@FierceMedDev: Merck will work with Sysmex to develop a colon cancer Dx that guides treatment for the drug Erbitux. Release | Follow @FierceMedDev

@VarunSaxena2: RT @AdvaMedUpdate: AdvaMed Opens China Office: official recognition will enhance AdvaMed's ability to partner w/ Chinese authorities. Release | Follow @VarunSaxena2

@MichaelGFierce: 'Quadrapeutics' works in preclinical study of hard-to-treat tumors. Story | Follow @MichaelGFierce

@EmilyWFierce: Devicemakers celebrate early regulatory wins despite 2013 setbacks. Report | Follow @EmilyWFierce

> Med tech incubator to assist Silicon Valley startups. Story

> OsteoSymbionics scores FDA clearance for craniofacial implant. More

> Digital health company Proteus bags $120M. Report

> Medtronic gets CE mark for its Duo insulin pump and glucose monitoring system. News

Biotech News

@FierceBiotech: Join @FierceBiotech's @JohnCFierce and a panel of experts at our Exec Breakfast in San Diego June 18th. More | Follow @FierceBiotech

@JohnCFierce: Love seeing $TEVA and $AZN provide huge peak sales projections on experimental drugs. Keep it coming. I will never forget. | Follow @JohnCFierce

@DamianFierce: "Marijn" rhymes with "Bahrain," not "Carmine," right? Release | Follow @DamianFierce

@EmilyMFierce: ICYMI yesterday: Omeros wins FDA blessing for eye treatment. Report | Follow @EmilyMFierce

> Prosensa gets an FDA green light for its once-failed DMD drug. News

> Teva buys into a blockbuster migraine drug rivalry with $825M Labrys buyout. More

> NPS throws ice water on $4B Shire rumor, but Wall Street keeps the faith. Article

> ASCO spotlight burns Puma shares. Item

> Sanofi CEO Viehbacher now calls beloved Boston biotech hub his home. Report

Biotech Research News

> Genetically engineered malaria parasite could expedite vaccine development. Article

> Alzheimer's compound gradually lowers amyloid in mice brains. Story

> Sangamo's gene editing tech fixes immune flaw in stem cell study. Article

> Biogen, Array strike preclinical autoimmune disease pact. Item

> Nektar cancer drug shrinks tumor growth in preclinical study. More

Pharma Manufacturing News

> FDA's OK for Boehringer Ingelheim plant gives it and Lilly hope on diabetes drug. Report

> Zydus recall flags another costly bottle mixup. Story

> Iran plant starts production of vet drugs but sets sights on human meds. More

> FDA catches Wockhardt U.S. plant using same spurious testing procedures as Indian plants. Article

> Alexion recalls Soliris for third time for particulate. Story

And Finally... Google Glass is entering the operating room. More (sub. req.)

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.